Literature DB >> 6766162

Native and activated properdin: interconvertibility and identity of amino- and carboxy-terminal sequences.

R G Medicus, A F Esser, H N Fernandez, H J Müller-Eberhard.   

Abstract

The development of a two-step purification procedure of native properdin with good yield has allowed the physical and chemical comparison of native and activated properdin. The two forms of properdin have identical electrophoretic mobility, subunit size, and amino- as well as carboxyl-terminal amino acid sequences. The two forms of properdin can be interconverted by using mild denaturing agents, indicating that the change in biologic activity is conformational. Circular dichroism analysis of properdin reveals a significant variability in the tertiary structure. However, the differences are a result of the method of purification and do not correspond to the biologic activity of the protein, because the spectra of the interconverted forms of properdin do not change. This indicates that the conformational transition that causes biologic activity changes is small, relative to the conformational variations produced by other conditions that do not alter the biologic activity.

Mesh:

Substances:

Year:  1980        PMID: 6766162

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.

Authors:  T R Kozel; M A Wilson; G S Pfrommer; A M Schlageter
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

2.  Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

Authors:  J A Schifferli; G Steiger; G Hauptmann; P J Spaeth; A G Sjöholm
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

3.  Resolution and analysis of 'native' and 'activated' properdin.

Authors:  T C Farries; J T Finch; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

4.  Prevalence of hereditary properdin, C7 and C8 deficiencies in patients with meningococcal infections.

Authors:  M Schlesinger; Z Nave; Y Levy; P E Slater; Z Fishelson
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

Review 5.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

Review 6.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

7.  The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.

Authors:  R G DiScipio
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

8.  Low ionic strength or chemical cross-linking of monomeric C3b increases its binding affinity to the human complement C3b receptor.

Authors:  M A Arnaout; N Dana; J Melamed; R Medicus; H R Colten
Journal:  Immunology       Date:  1983-02       Impact factor: 7.397

9.  Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

Authors:  J T Mayes; R D Schreiber; N R Cooper
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

10.  Clustering of neutrophil leucocytes in serum: possible role of C1q-containing immune complexes.

Authors:  G Sturfelt; H Jonsson; G Hellmer; A G Sjöholm
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.